Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-B7-H3/CD28 bispecific antibody XmAb808

A bispecific antibody directed against the tumor-associated antigen (TAA) and immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the co-stimulatory T-cell surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of anti-B7-H3/CD28 bispecific antibody XmAb808, this bispecific antibody binds to both B7-H3 on certain tumor cells and CD28 on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to B7-H3-expressing tumor cells, which may result in the CTL-mediated cell death of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-B7-H3/anti-CD28 bispecific antibody XmAb808
B7-H3 x CD28 bispecific antibody XmAb808
Code name:XmAb 808
XmAb-808
XmAb808
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search